Gongwing Biopharm

Gongwing Biopharm is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics. The company utilizes a proprietary macrocyclic drug discovery platform designed to target challenging protein-protein interactions (PPIs) and other historically undruggable targets. Its lead candidate, GW001, is a potent and selective macrocyclic SHP2 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Gongwing's pipeline primarily targets the RAS/MAPK signaling pathway, with additional programs focused on SOS1 and KRAS mutations. By integrating structural biology with advanced medicinal chemistry, the company aims to deliver high-impact precision medicines for oncology and other life-threatening diseases.